Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status

Abstract To evaluate and compare the performance of synthetic magnetic resonance imaging (SyMRI) in classifying benign and malignant breast lesions and predicting the expression status of immunohistochemistry (IHC) markers. We retrospectively analysed 121 patients with breast lesions who underwent d...

Full description

Bibliographic Details
Main Authors: Xiaojun Li, Zhichang Fan, Hongnan Jiang, Jinliang Niu, Wenjin Bian, Chen Wang, Ying Wang, Runmei Zhang, Hui Zhang
Format: Article
Language:English
Published: Nature Portfolio 2023-10-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-45079-2
_version_ 1797452997147492352
author Xiaojun Li
Zhichang Fan
Hongnan Jiang
Jinliang Niu
Wenjin Bian
Chen Wang
Ying Wang
Runmei Zhang
Hui Zhang
author_facet Xiaojun Li
Zhichang Fan
Hongnan Jiang
Jinliang Niu
Wenjin Bian
Chen Wang
Ying Wang
Runmei Zhang
Hui Zhang
author_sort Xiaojun Li
collection DOAJ
description Abstract To evaluate and compare the performance of synthetic magnetic resonance imaging (SyMRI) in classifying benign and malignant breast lesions and predicting the expression status of immunohistochemistry (IHC) markers. We retrospectively analysed 121 patients with breast lesions who underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and SyMRI before surgery in our hospital. DCE-MRI was used to assess the lesions, and then regions of interest (ROIs) were outlined on SyMRI (before and after enhancement), and apparent diffusion coefficient (ADC) maps to obtain quantitative values. After being grouped according to benign and malignant status, the malignant lesions were divided into high and low expression groups according to the expression status of IHC markers. Logistic regression was used to analyse the differences in independent variables between groups. The performance of the modalities in classification and prediction was evaluated by receiver operating characteristic (ROC) curves. In total, 57 of 121 lesions were benign, the other 64 were malignant, and 56 malignant lesions performed immunohistochemical staining. Quantitative values from proton density-weighted imaging prior to an injection of the contrast agent (PD-Pre) and T2-weighted imaging (T2WI) after the injection (T2-Gd), as well as its standard deviation (SD of T2-Gd), were valuable SyMRI parameters for the classification of benign and malignant breast lesions, but the performance of SyMRI (area under the curve, AUC = 0.716) was not as good as that of ADC values (AUC = 0.853). However, ADC values could not predict the expression status of breast cancer markers, for which SyMRI had excellent performance. The AUCs of androgen receptor (AR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), p53 and Ki-67 were 0.687, 0.890, 0.852, 0.746, 0.813 and 0.774, respectively. SyMRI had certain value in distinguishing between benign and malignant breast lesions, and ADC values were still the ideal method. However, to predict the expression status of IHC markers, SyMRI had an incomparable value compared with ADC values.
first_indexed 2024-03-09T15:16:28Z
format Article
id doaj.art-51b49d849878463095f76560374db710
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-03-09T15:16:28Z
publishDate 2023-10-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-51b49d849878463095f76560374db7102023-11-26T13:03:59ZengNature PortfolioScientific Reports2045-23222023-10-0113111010.1038/s41598-023-45079-2Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression statusXiaojun Li0Zhichang Fan1Hongnan Jiang2Jinliang Niu3Wenjin Bian4Chen Wang5Ying Wang6Runmei Zhang7Hui Zhang8Department of Medical Imaging, Shanxi Medical UniversityDepartment of Medical Imaging, Shanxi Medical UniversityDepartment of Breast Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen CenterDepartment of Radiology, The 2nd Affiliated Hospital of Shanxi Medical UniversityDepartment of Medical Imaging, Shanxi Medical UniversityDepartment of Pathology, The 2nd Affiliated Hospital of Shanxi Medical UniversityDepartment of Pathology, The 2nd Affiliated Hospital of Shanxi Medical UniversityDepartment of Radiology, The 2nd Affiliated Hospital of Shanxi Medical UniversityDepartment of Radiology, First Hospital of Shanxi Medical UniversityAbstract To evaluate and compare the performance of synthetic magnetic resonance imaging (SyMRI) in classifying benign and malignant breast lesions and predicting the expression status of immunohistochemistry (IHC) markers. We retrospectively analysed 121 patients with breast lesions who underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and SyMRI before surgery in our hospital. DCE-MRI was used to assess the lesions, and then regions of interest (ROIs) were outlined on SyMRI (before and after enhancement), and apparent diffusion coefficient (ADC) maps to obtain quantitative values. After being grouped according to benign and malignant status, the malignant lesions were divided into high and low expression groups according to the expression status of IHC markers. Logistic regression was used to analyse the differences in independent variables between groups. The performance of the modalities in classification and prediction was evaluated by receiver operating characteristic (ROC) curves. In total, 57 of 121 lesions were benign, the other 64 were malignant, and 56 malignant lesions performed immunohistochemical staining. Quantitative values from proton density-weighted imaging prior to an injection of the contrast agent (PD-Pre) and T2-weighted imaging (T2WI) after the injection (T2-Gd), as well as its standard deviation (SD of T2-Gd), were valuable SyMRI parameters for the classification of benign and malignant breast lesions, but the performance of SyMRI (area under the curve, AUC = 0.716) was not as good as that of ADC values (AUC = 0.853). However, ADC values could not predict the expression status of breast cancer markers, for which SyMRI had excellent performance. The AUCs of androgen receptor (AR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), p53 and Ki-67 were 0.687, 0.890, 0.852, 0.746, 0.813 and 0.774, respectively. SyMRI had certain value in distinguishing between benign and malignant breast lesions, and ADC values were still the ideal method. However, to predict the expression status of IHC markers, SyMRI had an incomparable value compared with ADC values.https://doi.org/10.1038/s41598-023-45079-2
spellingShingle Xiaojun Li
Zhichang Fan
Hongnan Jiang
Jinliang Niu
Wenjin Bian
Chen Wang
Ying Wang
Runmei Zhang
Hui Zhang
Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
Scientific Reports
title Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
title_full Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
title_fullStr Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
title_full_unstemmed Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
title_short Synthetic MRI in breast cancer: differentiating benign from malignant lesions and predicting immunohistochemical expression status
title_sort synthetic mri in breast cancer differentiating benign from malignant lesions and predicting immunohistochemical expression status
url https://doi.org/10.1038/s41598-023-45079-2
work_keys_str_mv AT xiaojunli syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT zhichangfan syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT hongnanjiang syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT jinliangniu syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT wenjinbian syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT chenwang syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT yingwang syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT runmeizhang syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus
AT huizhang syntheticmriinbreastcancerdifferentiatingbenignfrommalignantlesionsandpredictingimmunohistochemicalexpressionstatus